NCT00185120已完成4 期
A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 152
- 试验地点
- 39
- 主要终点
- Change in systolic blood pressure from the start of the study
研究概览
简要总结
A comparison of 2 different combinations of high blood pressure medications to treat hypertension
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Greater than 18 years of age
- •Patients with high blood pressure
排除标准
- •Hypertensive encephalopathy, stroke or transient ischemic attack within the past 6 months
- •History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months
- •Type 1 diabetes mellitus
结局指标
主要结局
Change in systolic blood pressure from the start of the study
次要结局
- Change in diastolic blood pressure from the start of the study
- Percent of patients who achieve target blood pressure goals
研究者
研究点 (39)
Loading locations...
相似试验
已完成
3 期
Combination of Olmesartan and Hydrochlorothiazide in Essential HypertensionEssential HypertensionNCT00430950Daiichi Sankyo1,011
已完成
不适用
Study of High-dose Olmesartan compared with Telmisartan on Blood pressure and Metabolism in Type 2 Diabetics with HypertensioJPRN-UMIN000006046niversity of Occupational and Environmental Health, Japan36
已完成
4 期
The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy SubjectsHealthyNCT00185055Daiichi Sankyo20
已完成
3 期
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination TherapyEssential HypertensionNCT01838850Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company344
已完成
3 期
Olmesartan in Essential HypertensionEssential HypertensionNCT00185172Sankyo Pharma Gmbh2,333